1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Genetic conditions
  5. Cystic fibrosis

Colistimethate sodium and tobramycin dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis

Technology appraisal guidance [TA276] Published date: 27 March 2013

  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History

Evidence

Review and download supporting evidence. Includes the full guideline if available.

Supporting evidence

  • Review decision
  • Review Decision – October 2015
  • Appendix A - RPP decision paper - October 2015 19 October 2015   PDF 17.03 KB
NICE
  • About NICE
  • Into practice
  • News
  • Contact us
  • Leave feedback
  • Jobs
  • Newsletters and alerts
  • Blog
  • Twitter
  • YouTube
  •   Facebook
  • LinkedIn

Explore

  • Guidance
  • Pathways
  • Standards and indicators
  • Evidence search
  • BNF
  • BNFC
  • Clinical knowledge summaries
  • Journals and databases

Reusing our content

  • Reuse information
  • NICE UK Open Content Licence

Get involved

  • Register as a stakeholder
  • Citizens council
  • Consultations
  • Fellows and scholars
  • Join a committee
  • Meetings in public
  • Student champions
  • Tenders
  • NICE and the public
  • Accessibility
  • Freedom of information
  • Syndication services
  • Glossary
  • Terms and conditions
  • Privacy notice

© NICE [year]. All rights reserved. Subject to Notice of rights.